Amgen Inc.

Vigil Neuroscience, Inc.

Yongwei Wu

Ryan D White

Jonathan B Houze

Gwenaella Rescourio

Haoxuan Wang

Vincent Santora

Alice R Wong

Timothy Hopper

Lara C Czabaniuk

Jane Panteleev

Maxence Bos

John Mancuso

Ivan Franzoni

Russell Graceffa

Daniel A Erlanson

Xiao Mei Zheng

John R Butler

Jesse M McFarland

Abhisek Banerjee

Joon Won Jeong

Jeffrey Iwig

Shuyan Yi

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2').  This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

N-cyano-7-azanorbornane derivatives and uses thereof

Growing community of inventors

Thousand Oaks, CA, United States of America

Yongwei Wu